Founded in 1986, Shire is a fast-growing global specialty biopharmaceutical company with 2008 revenues of $3 billion and over 3,700 employees worldwide. A global leader working to meet the needs of the specialist physician and the patients they serve, Shire today has a presence in 23 countries and medicines available in nearly 40 countries. We focus on the therapeutic areas of attention deficit and hyperactivity disorder (ADHD), gastrointestinal (GI), and genetic disorders. Encouraging our employees to be innovative, to take measured risks, and to act on the needs of our patients help define Shire and our people.
Our operation is structured in two complementary businesses - Human Genetic Therapies (HGT), and Specialty Pharmaceuticals - that are each supported by various corporate functions. Our HGT team specialises in researching, developing, and commercialising therapies for the treatment of rare genetic diseases caused by protein deficiencies. Shire's Specialty Pharmaceuticals team is made up currently of three business units - ADHD, GI, and Emerging Products. This team also oversees many other marketed medicines approved to help people around the world.
By encouraging trust and openness in all we do, Shire has evolved through strategic acquisitions into a unique, nimble organisation that is able to act quickly and take advantage of business opportunities as they arise. Through a culture that allows all employees to potentially impact and shape our business, Shire distinguishes itself from other biopharma organisations. Working as a team, our employees strive to continually achieve our purpose of enabling people with life-altering conditions to lead better lives.
We are always looking for talented people to join the Shire team. To learn more about Shire, visit www.shire.com. For more information on career opportunities with Shire, please visit: www.TimeToBeBrave.com.
Shire. To be as brave as the people we help.